OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Brastianos on Recent Data in High-Grade Meningiomas

April 4th 2023

Priscilla K. Brastianos, MD, reviews recent findings in high-grade meningiomas, including data generated in her laboratory.

Dr Pavlick on the Mechanisms of Action of RP1 in Cutaneous Melanoma

April 3rd 2023

Anna C. Pavlick, DO, discusses the mechanism of action of vusolimogene oderparepvec in patients with anti–PD-1–failed cutaneous melanoma.

Dr Daneshmand on the Investigation of Erdafitinib in NMIBC With FGFR2/3 Alterations

April 3rd 2023

Siamak Daneshmand, MD, discusses the rationale for investigating erdafitinib in patients with recurrent, intermediate-risk non–muscle invasive bladder cancer harboring FGFR3 or FGFR2 alterations.

Dr Ryan on the Implications of Updated Findings from JAVELIN Bladder 100 in Urothelial Cancer

April 3rd 2023

Christopher W. Ryan, MD, discusses the implications of updated findings from the phase 3 JAVELIN Bladder 100 trial in patients with locally advanced or metastatic urothelial cancer.

Dr. Friedlander on the FDA Approval of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

April 3rd 2023

Terence Friedlander, MD, discusses the significance of the FDA approval of frontline enfortumab vedotin combined with pembrolizumab in patients with urothelial carcinoma.

Dr McArthur on the Optimal Sequencing of Treatments in Metastatic TNBC

April 3rd 2023

Heather Lynn McArthur, MD, MPH, discusses key factors considered in the optimal sequencing of first and second line treatment option in patients with advanced triple-negative breast cancer.

Dr Hassan on the CHRYSALIS trial of Amivantamab in EGFR Exon 20–Mutated NSCLC

April 3rd 2023

Khaled Hassan, MD, discusses key results from the phase 1 CHRYSALIS trial of the bispecific antibody amivantamab-vmjw in non–small cell lung cancer expressing EGFR exon 20 insertion mutations.

Dr Hogen on Survival Outcomes With Neoadjuvant Chemotherapy and ICS in Epithelial Ovarian Cancer

March 31st 2023

Liat Hogen, MD, FRCSC, discusses the survival outcomes achieved with interval cytoreductive surgery following neoadjuvant chemotherapy in a study of patients with initial unresectable stage IV ovarian cancer.

Dr Ackroyd on the Assessment of Time Toxicity in Advanced/Recurrent Endometrial Cancer

March 31st 2023

Sarah Ackroyd, MD, MPH, discusses the rationale and key results from a study of time-related treatment burden in patients receiving treatment for advanced, recurrent endometrial cancer.

Dr Manning-Geist on Secondary Cytoreductive Surgery in Ovarian Cancer

March 30th 2023

Beryl Manning-Geist, MD, discusses findings from a study evaluating the effects of primary treatment modality on secondary cytoreduction outcomes in patients with high-grade ovarian cancer.

Dr Lee on Tremelimumab Plus Durvalumab in Ovarian Cancer

March 30th 2023

Jung-Yun Lee, MD, PhD, discusses primary efficacy and safety findings from the phase 2 KGOG3046/TRU-D trial in patients with newly diagnosed ovarian cancer.

Dr Mitzman on the Use of Adjuvant Atezolizumab After Chemotherapy in Resectable NSCLC

March 30th 2023

Brian Mitzman, MD, FACS, FCCP, discusses the use of adjuvant atezolizumab following platinum-based chemotherapy in patients with resectable non–small cell lung cancer.

Dr Kin on the Limitations of BCMA-Targeted Therapies in Myeloma

March 30th 2023

Andrew Kin, MD, discusses the limitations and unmet needs associated with the use of BCMA-targeted therapies in relapsed/refractory multiple myeloma.

Dr Johnson the Accuracy of Genomic Testing in Black Women With ER+ Breast Cancer

March 30th 2023

Nathalie McDowell Johnson, MD, FACS, discusses the accuracy of genomic testing in Black women with estrogen receptor-positive breast cancer.

Dr Berkenstock on ADC-Related Ocular Toxicities in Cervical and Ovarian Cancers

March 30th 2023

Meghan K. Berkenstock, MD, discusses common ocular toxicities associated with the use of novel antibody-drug conjugates, and the subsequent development of mitigation strategies for these treatment-related adverse effects in gynecologic cancers.

Dr Matulonis on the Management of Mirvetuximab Soravtansine-Related Toxicities in FRα+ Ovarian Cancer

March 30th 2023

Ursula A. Matulonis, MD, discusses common toxicities associated with mirvetuximab soravtansine-gynx, and how to properly manage these treatment-related adverse effects for patients with folate receptor alpha-high ovarian cancer.

Dr Mathews on Maintenance Olaparib in Ovarian Cancer

March 30th 2023

Cara A. Mathews, MD, discusses 7-year overall survival data from the phase 3 SOLO-1 trial in patients with ovarian cancer.

Dr Sikov on the Benefit of CDK4/6 Inhibitors in HR+/HER2-Negative Breast Cancer

March 29th 2023

William M. Sikov, MD, discusses the benefit of CDK4/6 inhibitors in the treatment of hormone receptor–positive/HER2-negative breast cancers.

Dr Malalur on the Implications of NALIRIFOX in Pancreatic Ductal Adenocarcinoma

March 29th 2023

Pannaga G. Malalur, MBBS, discusses the implications of the findings for the use of liposomal irinotecan plus 5-fluorouracil, leucovorin, and oxaliplatin in the frontline setting for patients with metastatic pancreatic ductal adenocarcinoma.

Dr Borthakur on the SELECT MDS-1 Trial in Newly Diagnosed MDS

March 29th 2023

Gautam Borthakur, MD, discusses the ongoing phase 3 SELECT MDS-1 trial in patients with newly diagnosed myelodysplastic syndromes.